GlobalData on MSN
Windward Bio doses first patients in Phase II SIRIUS COPD trial
The study aims to assess the safety, pharmacodynamics, pharmacokinetics and tolerability of HBM9378 for COPD.
COPD study initiation expands WIN378 development into a second major respiratory diseaseWIN378 is currently being evaluated in the Phase 2/3 ...
Lupin has partnered Spain's ERN to launch Luforbec for asthma and COPD, extending its respiratory franchise in Europe as the ...
Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results